| |
| |
|
| Insider
Information: |
Labrucherie Gil M |
| Relationship: |
Chief Financial Officer |
| City: |
San Carlos |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
319,155 |
|
|
Indirect Shares
|
94,335 |
|
|
| Direct
Value |
$423,139 |
|
|
|
Indirect Value
|
$383,839 |
|
|
| Total
Shares |
413,490 |
|
|
| Total
Value |
$806,978 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-6.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -181.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nektar Therapeutics |
NKTR |
SVP, COO & CFO |
2022-05-16 |
312,905 |
2008-11-14 |
0 |
Premium* |
|
|
Rezolute, Inc |
RZLT |
Director |
2022-05-04 |
0 |
2022-05-04 |
53,572 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Chief Financial Officer |
2023-10-04 |
6,250 |
2023-10-04 |
40,763 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-10-02 |
4 |
AS |
$24.45 |
$2,934,000 |
D/D |
(120,000) |
63,414 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-05-02 |
4 |
AS |
$85.63 |
$2,568,900 |
D/D |
(30,000) |
99,739 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-05-01 |
4 |
AS |
$83.65 |
$2,509,500 |
D/D |
(30,000) |
99,739 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-05-03 |
4 |
AS |
$82.86 |
$2,485,800 |
D/D |
(30,000) |
99,739 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2014-11-28 |
4 |
AS |
$17.02 |
$1,531,800 |
D/D |
(90,000) |
4,251 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-10-02 |
4 |
OE |
$11.34 |
$1,360,800 |
D/D |
120,000 |
183,414 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-02 |
4 |
AS |
$19.97 |
$1,008,629 |
D/D |
(50,000) |
266,973 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-04 |
4 |
AS |
$19.81 |
$990,500 |
D/D |
(50,000) |
266,973 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-03 |
4 |
AS |
$19.61 |
$980,500 |
D/D |
(50,000) |
266,973 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-07-10 |
4 |
AS |
$34.57 |
$864,250 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-06-17 |
4 |
AS |
$33.71 |
$842,750 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2015-12-03 |
4 |
AS |
$15.87 |
$714,166 |
D/D |
(45,001) |
5,251 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2015-11-11 |
4 |
AS |
$13.52 |
$608,400 |
D/D |
(45,000) |
4,751 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2015-09-23 |
4 |
AS |
$13.04 |
$586,787 |
D/D |
(44,999) |
4,751 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-09-16 |
4 |
AS |
$20.52 |
$513,000 |
D/D |
(25,000) |
152,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2014-12-01 |
4 |
AS |
$17.00 |
$510,000 |
D/D |
(30,000) |
4,251 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2019-11-13 |
4 |
AS |
$19.79 |
$494,750 |
D/D |
(25,000) |
227,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2015-10-06 |
4 |
AS |
$10.99 |
$494,550 |
D/D |
(45,000) |
4,751 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-08-26 |
4 |
OE |
$16.31 |
$489,300 |
D/D |
30,000 |
152,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-08-16 |
4 |
D |
$58.40 |
$479,289 |
D/D |
(8,207) |
113,059 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-08-14 |
4 |
AS |
$17.79 |
$444,750 |
D/D |
(25,000) |
127,935 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-02 |
4 |
OE |
$8.80 |
$440,000 |
D/D |
50,000 |
316,973 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-03 |
4 |
OE |
$8.80 |
$440,000 |
D/D |
50,000 |
316,973 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-04 |
4 |
OE |
$8.80 |
$440,000 |
D/D |
50,000 |
316,973 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2014-11-28 |
4 |
OE |
$4.65 |
$418,500 |
D/D |
90,000 |
94,251 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
